Research Article

Differentiating COVID-19 and dengue from other febrile illnesses in co-epidemics:

Development and internal validation of COVIDENGUE scores

Patrick Gérardin[1], Olivier Maillard[1], Léa Bruneau[2], Frédéric Accot[3], Florian Legrand[3,5], Patrice

Poubeau[3,4,5], Rodolphe Manaquin[3,4,5], Fanny Andry[3,4,5†], Antoine Bertolotti[1,3,4†], Cécile

Levin[3,4,5]

[1] Centre for Clinical Investigation - Clinical Epidemiology (CIC 1410), Institut National de la Santé et de

la Recherche Médicale (INSERM), Centre Hospitalier Universitaire de la Réunion, Saint Pierre,

Reunion, France

[2] Department of Public health and Research Support, Centre Hospitalier Universitaire de la Réunion,

Saint Denis, Reunion, France

[3] COVID-19 testing centre, Centre Hospitalier Universitaire de la Réunion, Saint Pierre, Reunion,

France

[4] Department of Infectious Diseases and Tropical Medicine, Centre Hospitalier Universitaire de la

Réunion, Saint Pierre, Reunion, France

[5] City to Hospital Outpatient Clinic for the care of COVID-19, Centre Hospitalier Universitaire de la

Réunion, Saint Pierre, Reunion, France

Corresponding Author: P. Gérardin, Center for Clinical Investigation (CIC1410), CHU

Réunion, BP 350, 97448 Saint-Pierre Cedex – Reunion, (patrick.gerardin@chu-reunion.fr)

[†] Contributed equally.

Short running head title: **Scores to distinguish COVID-19 from dengue and other febrile**

illnesses in co-epidemics

Abstract

Background. In a retrospective cohort study, we previously distinguished the factors associated with

coronavirus 2019 (COVID-19) or dengue from those associated with other febrile illnesses (OFIs). In

this study, we developed a scoring system to discriminate both infectious diseases.

Methods. Predictors of both infections were sought using multinomial logistic regression models

(OFIs as controls) in all subjects suspected of COVID-19 who attended the SARS-CoV-2 testing center

of Saint-Pierre teaching hospital, Reunion Island, between March 23 and May 10, 2020. Two

COVIDENGUE scores were developed and internally validated by bootstrapping for predicting each

infection after weighting the odd ratios according to a predefined rule. The discriminative ability of

each score was assessed using the area under the receiver operating characteristic curve (AUC). Their

calibration was assessed using goodness-of-fit statistics.

Results. Over 49 days, 80 COVID-19, 60 non-severe dengue and 872 OFI cases were diagnosed. The

translation of the best fit model yielded two COVIDENGUE scores composed of 11 criteria: contact

with a COVID-19 positive case (+3 points for COVID-19; 0 point for dengue), return from travel

abroad within 15 days (+3/-1), previous individual episode of dengue (+1/+3), active smoking (-3/0),

body ache (0/+5), cough (0/-2), upper respiratory tract infection symptoms (-1/-1), anosmia (+7/-1),

headache (0/+5), retro-orbital pain (-1/+5), and delayed presentation (>3 days) to hospital (+1/0).

The AUC was of 0.79 (95%CI 0.76-0.82) for COVID-19 score and of 0.88 (95%CI 0.85-0.90) for dengue

score. Calibration was satisfactory for COVID-19 score and excellent for dengue score. For predicting

COVID-19, sensitivity was of 97% at the 0-point cut-off and specificity approximated 99% at the 10-

point cut-off. For predicting dengue, sensitivity approximated 97% at the 3-point cut-off and

specificity 98% at the 11-point cut-off.

Conclusions. In conclusion, the COVIDENGUE scores proved discriminant to differentiate COVID-19

and dengue from other febrile illnesses in the context of SARS-CoV-2 testing center during a co-

epidemic. Further studies are needed to validate or refine these scores in other settings.

Author Summary

In the last two years, several countries not only have faced the impact of the coronavirus 2019

(COVID-19) but also dengue epidemics simultaneously, evoking an overburden to healthcare

systems. On Reunion Island, southwestern Indian ocean, dengue virus is circulating since 2004 under

an endemo-epidemic pattern with outbreaks peaking between March and May and has prominently

intensified annually since 2015. Regarding COVID-19, Severe Acute Respiratory Syndrome

Coronavirus-2 (SARS-CoV-2) emerged in March 2020 and was brought from the Bahamas to the

island. COVID-19 and dengue have been deemed clinically similar, especially within the first two days

from symptom onset. In the framework of a cohort study conducted at a SARS-CoV-2 testing center

between March 23 and May 10, 2020, we developed two scores aimed at predicting both infections.

The discriminative ability (the ability to diagnose each infection) was satisfactory to good for COVID-

19 (area under receiver operating characteristic curve [AUC] 0.79, 95% confidence interval [CI] 0.76-

0.82) and good for dengue (AUC 0.88, 95%CI 0.85-0.90). The calibration (the adequacy between

predicted and observed infections) was satisfactory for both scores. Each score was user-friendly and

provided an easy guidance for predictive analysis, whether in strategies maximizing the prediction or

the exclusion of each infection.

Keywords: coronavirus; COVID-19; severe acute respiratory syndrome; SARS-CoV-2; dengue;

arbovirus; flavivirus; epidemics; pandemics; cohort study; risk factors; multivariate analysis; logistic

regression; multinomial logistic regression; prediction model; score

Background

Prompt identification and management of overlapping COVID-19 and dengue infections may prevent cases of both viral diseases from deteriorating [1]. Moreover, it can avoid events of hospitalization in the Intensive Care Unit (ICU) and nosocomial transmission of both infections which may be useful whenever syndemics stress healthcare systems [2]. For public health, more rapid quarantine, contact tracing and vector control measures may help to mitigate the dynamics of both epidemics [2,3].

Since Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) spread globally, several countries have been facing dengue epidemics with the fear of increased mortality in the most vulnerable populations [4]. Moreover, the absence of both highly sensitive and specific rapid diagnostics tests may have hampered discrimination between the two separate diagnoses possibly leading to misdiagnoses and the implementation of inadequate countermeasures in emergency situations [4]. On Reunion Island, a French overseas territory located in the southwestern Indian ocean region known to have host one of the largest chikungunya outbreaks [5], dengue virus (DENV) is endemic with annual epidemics occurring since 2015 [6]. Moreover COVID-19, which emerged in March 2020, has established an autochthonous transmission since August 2020 [7].

Surprisingly, most prediction models in the field of COVID-19 research have been dedicated to prognosis and not to the identification of people diseased from infection nor at risk of being infected [8]. Given that differential diagnosis between COVID-19 and dengue was difficult, we set-up a cohort study and developed a multinomial logistic regression model (MLR) aimed at distinguishing SARS-CoV-2 or DENV infections from other febrile illnesses (OFIs) during the first COVID-19 introductive pandemic wave [9].

Herein, we furthered our previous reflection to improve the predictive capability of our model in testing the hypothesis that the more variables included in the model, the better the discrimination between the diseases [10].

The objective of this study was to develop and internally validate a scoring system able to predict both infectious diseases which to date had never been performed.

Methods

Study design, study setting and population

A retrospective cohort study was conducted using prospectively collected data between 23 March

A retrospective cohort study was conducted using prospectively collected data between 23 March

and 10 May 2020, on all participants screened for COVID-19 within the UDACS (*Unité de Dépistage*

Ambulatoire du COVID-19 Sud) of Saint-Pierre which is one of the two SARS-CoV-2 testing centers of

the *Centre Hospitalier Universitaire Réunion* (CHU Reunion) providing care for the general population

at the time. People without symptoms or with co-infections were excluded from the study.

Consecutively arriving outpatients to the SARS-CoV-2 testing center were informed of the

study both verbally and by means of an informational document. Adults, as well as children under

the age of 18 years (having the additional verbal consent of their parent or legal guardian) who

expressed no opposition were asked to answer a questionnaire and were personally interviewed by a

nurse in accordance with the French legislation on bioethics for retrospective research.

Patients' medical records were retrospectively reviewed and anonymized data were collected

in standardized forms according to the MR-004 procedure of the *Commission Nationale de*

l'Informatique et des Libertés (the French Information Protection Commission). The ethical character

of this study on previously collected data was approved by the Scientific Committee for COVID-19

research of CHU Reunion and anonymized data were registered on the Health Data Hub (N°

F20201021104344/October, 2020).

Data collection and gold standard procedure

The questionnaire included information on: i) demographics (gender and age), ii) occupation, iii) risk

factors (smoking, obesity, return from travel abroad during the 15 previous days), iv) comorbidities

(diabetes, hypertension, cardiovascular disease, chronic obstructive pulmonary disease, cancer,

previous episode of dengue and "other comorbidities"), v) intra-household and individual exposure

to SARS-CoV-2, vi) individual symptoms (fever, cough, dyspnea/shortness of breath, body aches,

diarrhea, gut symptoms, ageusia, metallic taste, anosmia, fatigue, headache, retro-orbital pain and

upper respiratory tract infection symptoms) and vii) treatment (antihypertensive drugs and/or

hydroxychloroquine). Patients' temperature, pulse rate, respiratory rate, and oxygen saturation

(SpO$_2$) were also measured during the consultation, as well as the presence of cough and/or anxiety.

People reporting symptoms were examined by a medical resident or a senior infectious disease

specialist in accordance with routine care procedures.

All participants were screened for COVID-19 by a nurse using a nasopharyngeal swab for 20

seconds in one nostril [11]. Each sample was administered for a SARS-CoV-2 reverse transcription-

polymerase chain reaction (RT-PCR) using the Allplex 2019-nCov^{TM} assay (Seegene, Seoul, Republic of

Korea) or an in-house kit (CNR Pasteur) targeting N, RdRP and E genes, or N and IP2/IP4 targets of

RdRP depending on which assay was used. Moreover, each participant of the study that was

suspected of having dengue was tested for NS1 antigen using an OnSite^{TM} Duo dengue Ag-IgG-IgM

rapid diagnostic test (CTK Biotech, San Diego, CA, USA). If these patients had a negative result, they

were explored further with a DENV RT-PCR or a dengue serology panel according to the timing of

symptoms.

Statistical analysis

Proportions between COVID-19, dengue, and non-COVID-19 non-dengue OFI patients were

compared using Chi square or Fisher exact tests, where deemed appropriate. Bivariable and

multivariable multinomial logistic regression (MLR) models were fitted within Stata14® (Statacorp,

College Station, Texas, USA) to identify independent predictors of COVID-19 and dengue using OFIs

as controls.

The first step of the process included fitting a full MLR model with all significant covariates

identified by bivariable analysis [9]. From the candidate predictors, we used a backward stepwise

selection procedure to drop out non-significant variables (output if $P>0.05$). At this second step, we

built a parsimonious MLR model with all significant predictors. In this model, an adaption of the

Hosmer-Lemeshow goodness-of-fit chi2 test was used for MLR models with polytomous categorical

outcomes [12] (hereafter named MHL test for multinomial Hosmer-Lemeshow) to minimize the

discrepancy between predicted and observed events. In these analyses, crude, and adjusted odds

ratios (OR) and 95% confidence intervals (95% CI) were assessed using the binomial and Cornfield

methods respectively.

Based on the assumption that if there are more variables, there will be better discrimination

[10], we added variables that were ruled out at the borderline of significance during the backward

stepwise elimination process to our previous 9-covariate parsimonious model [9].

The strategy of this third step is detailed in the text file S1.

Weighted analyses on the overall inverse probability of hospitalization to assess the potential

for selection bias and to test the robustness of the identified predictors were performed next.

Lastly, from the best fit MLR compromise model, we derived two simple scores, the

COVIDENGUE scores (one for COVID-19 and, one for dengue) after weighting the OR according to a

predefined rule (S1 Table). This rule gave a weight to all the model covariates (no matter their

significance) to maximize the possible combinations and to provide the largest range of values which,

theoretically, enables the best discrimination.

The discriminative ability of the models and of the COVIDENGUE scores (*i.e.,* the model and

score performances) for the diagnosis of COVID-19 and dengue were tested using receiver operating

characteristic (ROC) plot analyses which considers ROC plots and areas under ROC curves (AUC) with

their 95%CIs [13]. Discrimination is usually considered as null when the AUC is 0.5, poor when

between 0.5 and 0.7, satisfactory between 0.7 and 0.8, good between 0.8 and 0.9, excellent between

0.9 and 1, and perfect when the AUC equals 1. In addition, we provided classification plots to assess

the discriminative ability of COVIDENGUE scores conditional to absolute risk thresholds [14]. Finally,

scores performances were internally validated by using bootstrapping (2000 replicates).

The calibration of the COVIDENGUE scores (*i.e.,* the adequacy between predicted and

observed events) was evaluated using state-of-art calibration plots [15] and Hosmer-Lemeshow tests

for MLR and binomial logistic regression models [12,16], as well as with event-based or risk-based

calibration plots which were displayed over the range of MHL deciles of predicted risks.

The diagnostic performance of each COVIDENGUE score cut-off was displayed in terms of

sensitivity, specificity, positive likelihood ratio (LR+), negative likelihood ratio (LR-), positive

predictive value (PPV), negative predictive value (NPV) and diagnostic accuracy.

For all these analyses, observations with missing data were ruled out, tests were two-tailed,

and a *P*-value less than 0.05 was considered as statistically significant.

The full details of the methods can be found in the text file S1. The results were reported

following both the STROBE and TRIPOD reporting guidelines for observational studies and prediction

models (text file S2), respectively [17,18].

Results

Characteristics of the study population

Between 23 March and 10 May 2020, 1,715 subjects were admitted to the UDACS for screening for or diagnosis of COVID-19. Over this 6-week period, the lab did not diagnose any cocirculation of influenza or non-influenza respiratory viruses.

As part of an expanded screening week dedicated to all admissions to our hospital, 370 subjects who were screened opportunistically and 332 fully asymptomatic subjects were ruled out leaving 1,013 outpatients eligible for this analysis. The study population is shown in Figure 1. The characteristics of the 1,013 of patients who consulted the COVID-19 screening center during the COVID-19 dengue co-epidemics are presented in S2 Table.

COVID-19 was diagnosed in 80 patients (7.9%) and dengue in 61 patients (6.0%) while 872 patients tested negative and were clinically considered as non-COVID-19, non-dengue subjects. Interestingly, COVID-19 patients presented themselves later in the course of the illness compared to patients with dengue or OFIs (time elapsed since symptom onset, 7.5 days versus 4.2 days or 6.3 days, $P<0.001$). Dengue was more likely to be symptomatic than COVID-19 as exemplified by higher frequencies of fever, body ache, gut symptoms, fatigue, headache, and retro-orbital pain, as well as a higher need for physical examination. However, COVID-19 exhibited longer durations of fatigue and rhinorrhea.

Bivariate and multivariate analyses

The crude relationships between the sociodemographic, epidemiological, and clinical characteristics in cases of COVID-19, dengue and OFIs are presented in S3 Table.

Bivariable analysis identified anosmia, the return from travel abroad during the previous 15 days, contact with a COVID-19 positive case and delayed presentation (beyond three days since symptom onset) as candidate predictors for COVID-19, whereas healthcare workers and active smokers as those protected against COVID-19. Headache, retro-orbital pain, body ache, fatigue, gut

symptoms, and previous individual episode of dengue were potential predictors for dengue, while

the recent return from travel abroad and cough were potential protective factors against dengue.

Interestingly, Upper Respiratory Tract Infection (URTI) symptoms provided protection against both

infections (which means they were associated with OFIs), while the role of fever and ageusia was less

clear, these being associated with both diagnoses of interest (S3 Table).

The variables that were significant in the bivariable analysis were entered into a full

multivariable MLR model (S4 Table). This generated 4% of missing observations (n=46). It supported

the role of anosmia, contact with a COVID-19 positive case and recent return from travel abroad as

independent predictors of COVID-19 as well as an association of active smokers to protection against

COVID-19. In turn, previous individual episodes of dengue, body ache, headache and retro-orbital

pain were independent predictors of dengue, while cough was less likely to be observed with this

infection. As for the bivariable analysis, URTI symptoms were indicative of OFIs. Alternatively, fever

proved non discriminant even though it was far more common with dengue which motivated its

exclusion from further analyses. As in our previous analysis [9], these findings were contrasted by the

weighting on the inverse probability of hospitalization rates (S5 Table).

After multicollinearity analysis, control of overfitting and unnecessary adjustments, the best fit

MLR compromise model (based on AIC and BIC metrics) included eleven covariates (Table 1). This

confirmed the role of anosmia, contact with a COVID-19 positive case and/or recent return from

travel abroad as independent predictors of COVID-19, as well as the role of body ache, headache,

previous individual episode of dengue and retro-orbital pain as predictors of dengue. Conversely, in

this model, active smoking, cough, and URTI symptoms were considered as protective factors against

COVID-19, dengue, or both.

Goodness-of-fit and discrimination indicators of the MLR models are displayed in S6 Table. We

made the assumption that the best fit compromise model could be achieved with the eleven

abovementioned covariates. The AUCs of the model were of 0.80 (95%CI 0.74-0.86) for COVID-19

and 0.89 (95%CI 0.84-0.92) for dengue in the primary analysis (Figure 2, panel a), and of 0.80 (95%CI

0.73-0.86) and 0.88 (95%CI 0.84-0.92) after bootstrapping, respectively. Further adjustment on both

age and/or gender did not improve the AUC of the model to a point sufficient enough to change

interpretation when considering AUC boundaries (S6 Table).

Score development and internal validation

Based on this final model, we derived two COVIDENGUE scores. For a better appropriation, we

decided to set the weight of each dengue clinical criterion at 5 points. With this exception, the

weighting scale was as described in S1 Table.

The translation of the final MLR model into two COVIDENGUE scores was satisfactory. This step

showed barely a 1-point loss in the discriminative ability for both COVID-19 and dengue and a

superimposition of model and score ROC plots (Figure 2, panel b and panel c).

The median value of the COVID-19 score was 1 (Q_1-Q_3: 0 to 3, range: -4 to 14) and the median

value of the dengue score was 3 (Q_1-Q_3: -1 to 7, range: -4 to 18). In the primary analysis, the

discriminative ability of the scores was satisfactory to good for COVID-19 (AUC 0.79, 95%CI 0.76-0.82)

and good for dengue (AUC 0.88, 95%CI 0.85-0.90) (Figure 2, panel d). Interestingly, the dengue score

exhibited higher true positive rates than the COVID-19 score (which means false negative cost was

minimized versus the false positive cost) in risk thresholds higher than 0.4. COVID-19 had higher

false positive rates in risk thresholds under 0.5 than the dengue scores (which means FP cost was

minimized versus FN) (S1 Fig.).

After bootstrapping, when considering confidence intervals, the discriminative ability was

between poor and good for COVID-19 (AUC 0.75, 95%CI 0.68-0.82) and good for dengue (AUC 0.86,

95%CI 0.81-0.90), which represented an AUC loss of five points and three points from the final MLR

model, respectively.

Overall, the calibration of the COVIDENGUE scores as shown by calibration plots (S1 Fig.) and

MHL tests (S7 Table and S8 Table) was deemed satisfactory albeit prone to underfitting for COVID-19

(slope: 1.22, intercept 0.08; chi2 (6) 1.75, *P*=0.9416), whereas it was excellent and consensual for

dengue (slope: 0.97, intercept 0.12; chi2 (8) 6.78, *P*=0.5605). Strikingly, despite few discrepancies

between predicted and observed events (S2 Fig. and S3 Fig., panel a and panel c), and a trend

towards underprediction of COVID-19 events (S4 Fig., panel a), the MHL test of both COVIDENGUE

scores was well balanced across the deciles of predicted risks (S7 Table and S8 Table) and their

calibration displayed other metrics better than those of the reference model (S9 Table).

For overall COVID-19 prediction, a threshold of 0 points displayed a sensitivity of 97.3% (95%CI

96.2%-98.3%) and a NPV of 99.0% (95%CI 98.4%-99.6%), while a threshold of 10 points displayed a

specificity of 98.8% (95%CI 98.1%-99.5%) and a PPV of 65.1% (95%CI 62.1%-68.1%). A 3-point cut-off

maximized both sensitivity and specificity (78.1% and 63.7%, respectively). Regardless of COVID-19

prevalence, the COVID-19 score was effective in excluding COVID-19 (LR- <0.10) for negative score

values under -1, whereas it was effective for diagnosing COVID-19 (LR+ >10) with score values higher

than 7. The detailed performances of the COVID-19 score are presented in S10 Table, its intrinsic and

extrinsic properties in Figure 3 (Panel a to panel d). For COVID-19 individual risk prediction, the

estimated probability of being infected derived from the COVID-19 score was $Prob_{(Y=1/x)} = 1 / (1 + exp^{-(-3.698086 + 0.3533028 \times score\ value)})$.

For dengue overall prediction, a threshold of 3 points displayed a sensitivity of 96.7% (95%CI

95.5%-97.8%) and a NPV of 99.7% (95%CI 99.4%-100%) while a threshold of 11 points displayed a

specificity of 97.7% (95%CI 96.7%-98.6%) and PPV of 40.3% (95%CI 37.2%-43.3%). A 6-point cut-off

maximized both sensitivity and specificity (83.3% and 71.7%, respectively). Regardless of dengue

prevalence, the dengue score was effective in excluding dengue (LR- <0.10) for score values under 4,

whereas it was effective for diagnosing dengue (LR+ >10) with score values higher than 10. The

detailed performances of the dengue score are presented in S11 Table, its intrinsic and extrinsic

properties in Figure 3 (Panel a to panel d). For dengue individual risk prediction, the estimated

probability of being infected derived from the dengue score was $Prob_{(Y=1/x)} = 1 / (1 + exp^{-(-5.508826 + 0.4406125 \times score\ value)})$.

Discussion

In this study, COVIDENGUE scores were developed and internally validated. An eleven covariate-based prediction model aimed at distinguishing COVID-19 from dengue and other febrile illnesses at their clinical onset was made in the context of cocirculation of SARS-CoV-2 and DENV. Overall, the predictive performance of the score, meaning the ability to diagnose or to rule out infection, was good for dengue and satisfactory for COVID-19, while calibration performance meaning the ability to minimize the discrepancy between expected and observed events, was at least satisfactory on multiple metrics of goodness-of-fit statistics. The dengue score for which symptoms were good predictors, displayed both better sensitivity and a higher negative predictive value while the COVID-19 score for which risk factors were paramount, proved more specific and had a higher positive predictive value across the whole range of cut-offs.

Strengths and limitations

A scoring system should have both construct and content validity. It must be able to be reproduced over time and across geographic and methodological boundaries. It must also be accurate (calibration and discrimination) and clinically meaningful [19]. Before this study, we previously assumed that COVID-19 and dengue diagnoses could be affected by a misclassification bias which could stem from the poor sensitivity of both SARS-CoV-2 molecular and DENV NS1 antigen tests rather than from their false positives [9]. This putative bias was believed to be minimal given that, firstly, on Reunion Island, like anywhere else during the rise of the COVID-19 pandemic [20], there was little cocirculation of other respiratory viruses that could have competed with SARS-CoV-2 and caused false negatives, [21] and secondly, for COVID-19, negative samples were retested by RT-PCR upon onset of new symptoms, meaning that rapid antibody or antigenic tests were ruled out, while for dengue, the workup was completed by a RT-PCR or a serology test to downsize false negative and false positive proportions [22-24]. This caution decision rule likely pledges the diagnostic accuracy of our gold standards.

Interestingly, the calibration of both scores was satisfactory to excellent and displayed

measures close to the theoretical model from which they were derived based on a set of various

goodness-of-fit metrics. Notwithstanding a relatively small study population, the diagnostic accuracy

of gold standards, along with the acceptable calibration properties ensure the validity of construct of

the COVIDENGUE scores and the reliability of their predictions at the individual level for the dengue

score, while, together with their discriminative ability, also lend support to their clinical utility [25].

The COVIDENGUE scores were developed using MLR [9] which is the gold standard method for

assessing non-ordered polytomous categorical outcomes [26,27]. Except for active smoking whose

protective effect against SARS-CoV-2 infection remains a matter of debate among researchers

[28,29], all predictors retained to build the scores had been previously identified as relevant

indicators of COVID-19 or dengue or associated with OFIs (especially respiratory infections) [29-40]

This ensures both the validity of content of this scoring system and the possibility of contrasted

predictions. For example, international travel had been identified as a source of COVID-19 during the

first pandemic wave [34,35]. In a recent Colombian study [38], dengue proved more symptomatic

than COVID-19 and dengue patients came to the hospital in greater numbers than COVID-19

patients. In Brazil's Amazonian basin, prior to a dengue infection, as diagnosed by positive IgG

antibodies was associated with twice the risk of clinically apparent COVID-19 [36]. The external

validity of the other predictors has been discussed thoroughly in our previous study [9]. Interestingly,

similar to our first analysis, weighting on the inverse odds of hospitalization abrogated the

significance of a few predictors (Table 1 versus S5 Table), which suggests a contrast in our findings at

the population level and motivates further validation studies in the primary care setting.

Notably, this hospital-based study was conducted in a SARS-CoV-2 screening center which may

have underestimated the real incidence of dengue and introduced another information bias in that

dengue patients could have been potentially directed towards other units or even underreported

given the lack of epidemiological predictors reported for dengue [9]. This potential limitation of the

validity of content should be investigated in future studies by adding more risk factors for dengue to

refine our models. Lastly, our scoring system was composed of only clinical and epidemiological

criteria. It was user-friendly for diagnosis purposes which should facilitate its utilization across

different settings while also helping its external validation.

Interpretation

For epidemiological and clinical practices, the overall performance of a prediction model relies first

on its discrimination [13]. In this perspective, ROC plots do not offer more information than the AUC

to indicate the discriminative ability [13,14]. In this study, we demonstrated that the discriminative

ability of the models could be improved only at the unreasonable cost of complexity (20-item model),

or when adding age to the COVID-19 model; a factor whose effect might change according to the

context (S6 Table). This study also showed that the translation of the model into two scores was not

accompanied by a significant loss in discriminative ability (Figure 2) which suggests an adequate

weighting of the scores.

Importantly, we provided classification plots which may offer more information for decision-

making conditional to risk thresholds [13,14]. Overall, classification plots may reveal a better ability

of the COVID-19 score to predict non-events (OFIs) and a better ability of dengue score to predict

events (dengue). Moreover, at lower risk thresholds the COVID-19 score exhibited a lower cost of FP

than the dengue score. For example, when the event risk was 0.2, the COVID-19 score yielded a 0.5:1

FN to FP ratio while it was 1:1 for the dengue score (Figure S1). These results aligned with a trend

towards a better specificity for the COVID-19 score than for the dengue score across the range of cut-

off values (Figure 3). Conversely, at higher risk thresholds (>0.5), when it came to predict an event,

the dengue score displayed a better sensitivity (in other words, higher TP rate, or a lower cost of FN

versus FP cost). Taken together with respect to the SARS-CoV-2 strategy of testing, isolating, and

tracing, our findings encourage evaluating the addition of clinical or biological discriminative

variables [38,39] in the COVID-19 score to improve its sensitivity across the risk thresholds while in

regard to the dengue strategy of testing, isolating, and targeted vector control, they encourage the

fitting with more specific epidemiological variables highly predictive of an infective bite by an *Aedes*

mosquito.

At an individual risk level, predictions should be guided using first of all calibration

performances (calibration plots and goodness-of-fit metrics) [24]. Our findings showed that the

calibration of the models (Table S6 to S8) and their derived scores (Table S9) were excellent and

consensual for dengue which enables individual risk prediction and satisfactory for COVID-19 which

suggests caution for individual risk prediction.

Generalizability

The COVIDENGUE scores were developed from data acquired within a hospital-based SARS-CoV-2

testing center on Reunion Island which is a tropical setting where dengue co-circulated early on

during the first pandemic wave at a time when there was no possibility to screen for COVID-19

outside the hospital. The circulation of the SARS-CoV-2 variant was furthermore unknown and the

population of infected people were mainly composed of relatively healthy travelers [9,35]. Thus,

although our center served an ambulatory healthcare driven population, the scores will have to be

validated in primary care settings before being broadly used in the community. They will also have to

be validated in the highly comorbid autochthonous population of the island [9,35].

In future research, the scores should be studied in the context of newly circulating SARS-CoV-2

variants as well as in the context of populations immunized against dengue or COVID-19. On Reunion

Island, the first wave of SARS-CoV-2 circulation ended in June 2020 as a result of the influence of the

first national lockdown. The second wave began in August 2020 during the winter season of the

region and was concomitant to the spread of the D614G mutation in Europe [7]. Since this period,

SARS-CoV-2 transmission has been mainly autochthonous and successively maintained through the

circulation of both South African (B.1.351/501Y.V2) and the Indian (B.1.617/21APR-02) variants of

concerns (VOCs). While the clinical presentation of dengue appears to be different between DENV-2

and DENV-1 serotype infections (DENV-1 has been predominant on the island since 2020) on top of

the proportions of secondary infections [41], it is not yet clear whether the prevalence of COVID-19

has changed throughout the circulating VOCs despite a trend towards increased severity reported

with the UK (B.1.1.7/501Y.V1) [42], along with the Brazilian (P.1/501Y.V3) [43], South African [44], or

Indian variants [45]. The same could be said to the potential for more clinically apparent

manifestations of COVID-19 when DENV infection precedes SARS-CoV-2 infection [36] as well as the

potential for higher severity with SARS-CoV-2 DENV co-infections [2]. Both have to be fully

investigated in the future with the diagnostic value of the COVIDENGUE scores evaluated.

Implications

For individual risk prediction and clinical practice, the equations of estimated probability of being

diagnosed as infected derived from the scores could be used to define individual risks conditional to

adequate calibration. Herein, we have shown that the COVIDENGUE scores could be useful to

diagnose dengue patients in a tropical SARS-CoV-2 screening center, however they deserved further

improvements for diagnosing COVID-19.

For public health purposes, the score values could be incorporated into testing strategies and

guided with mitigation interventions whenever routine biological testing is ineffective. For clinical

research, the cut-off values could serve to risk stratification in new diagnostic studies and the

COVIDENGUE scores items incorporated into propensity scores. For benchmarking of prediction

models, the predicted risk probabilities of a new model could also be summed up and compared to

the total number of infected individuals (to define risk thresholds) under the assumption that such an

observed-to-predicted risk ratio together with the slope of the calibration plots and the Hosmer-

Lemeshow chi2 test probability, would be close to one, to underlie the adequate calibration of the

new model.

When it comes to testing the external validity of the COVIDENGUE scores in a different

epidemiological context, or to improving their predictive performances by adding or removing

variables within a new model, investigators will have to consider using calibration plots and

goodness-of-fit statistics to see whether the model is properly calibrated and could apply to

individual risk prediction. Such novel investigations should delve deeper into demonstrating the

clinical use while providing new indicators such as the IDI (Integrated Discrimination Improvement)

and/or the net benefit from classification plots or decision curve analyses [13,14].

Conclusions

In conclusion, the COVIDENGUE scores proved discriminant to differentiate COVID-19 and dengue

from OFIs in the context of SARS-CoV-2 testing center during a co-epidemic. Further studies are

needed to validate or refine these scores in other settings.

Acknowledgments

The authors are indebted to the staffs of the Department of Infectious Diseases and Tropical

Medicine, especially Dr Yatrika Koumar, and the SARS-CoV-2 testing center with special appreciation

given to Dr Antoine Joubert and the nurses who performed the questionnaires. The authors would

also like to thank the biologists at CHU de La Réunion for their timely diagnosis, the participants for

their interest in research and AcaciaTools for their reviewing and medical writing services.

Supporting information

Supplementary material is available online. While the supplementary tables have been copyedited, the methodological appendix and the Venn diagram have not been copyedited and are the sole responsibility of the authors. Questions and comments about these should be addressed to the corresponding author. STROBE and TRIPOD checklists (text file S2).

Notes

Author's contributions.

Conceptualization: Fanny Andry, Patrick Gérardin, Cécile Levin. Data curation: Patrick Gérardin. Formal analysis: Patrick Gérardin, Antoine Bertolotti, Olivier Maillard, Léa Bruneau, Cécile Levin. Investigation: Frédéric Accot, Florian Legrand, Patrice Poubeau, Rodolphe Manaquin, Fanny Andry, Antoine Bertolotti, Cécile Levin. Methodology: Patrick Gérardin. Project administration: Fanny Andry. Resources: Cécile Levin. Software: Patrick Gérardin. Supervision: Olivier Maillard, Antoine Bertolotti. Validation: Patrick Gérardin, Cécile Levin. Visualization: Patrick Gérardin. Writing – original draft: Patrick Gérardin. Writing – review & editing: Patrick Gérardin, Olivier Maillard, Léa Bruneau, Frédéric Accot, Florian Legrand, Patrice Poubeau, Rodolphe Manaquin, Fanny Andry, Antoine Bertolotti and Cécile Levin.

List of abbreviations (alphabetic order)

aOR: Adjusted odds ratio

AUC: Area under receiver operating characteristic curve

CIR: Cumulative incidence rate (attack rate)

CNR: *Centre national de reference*

COVID-19: Coronavirus 2019

DENV: Dengue virus

ICU: Intensive Care Unit

MHL test: Multinomial Hosmer-Lemeshow test

MLR: Multinomial logistic regression

OFIs: Other febrile illnesses

RT-PCR: Reverse transcription – polymerase chain reaction

SARS-CoV-2: Severe Acute Respiratory Syndrome Coronavirus 2

SpO2: Pulse oxymetry

UDACS: *Unite de dépistage ambulatoire du coronavirus sud*

URTI: Upper respiratory tract infection

VOCs: variants of concerns

95% CI: 95% confidence interval

Funding: None

Potential conflicts of interest: All authors would like to report that there are no conflicts of interest

in relation to this research. All authors have signed the ICMJE disclosure form for potential conflicts

of interest.

Data availability statement: Data are entirely accessible through a data repository through the

publication of this article.

References

1. Caron M, Paupy C, Grard G, Becquart P, Mombo I, Nso BB, et al. Recent introduction

and rapid dissemination of Chikungunya virus and Dengue virus serotype 2 associated

with human and mosquito coinfections in Gabon, central Africa. Clin Infect Dis 2012; 55:

e45-53. http://dx.doi:10.1093/cid/cis530. Epub 2012 Jun 5.

2.   Mejia-Parra JL, Aguilar-Martinez S, Fernandez-Mogollon JL, Luna C, Bonilla-Aldana DK,

Rodriguez-Morales AJ, et al. Characteristics of patients coinfected with Severe Acute Respiratory

Syndrome Coronavirus 2 and dengue virus, Lambayeque, Peru, May–August 2020: A

retrospective   analysis.   Travel   Med   Infect   Dis   2021;   43:   102132.

https://dx.doi/10.1016/j.tmaid.2021.102132. Epub 2021 Jun 26.

3.   Huang SY, Lee IK, Wang L, Liu JW, Hung SC, Chen CC, et al. Use of simple clinical and

laboratory predictors to differentiate influenza from dengue and other febrile illnesses in

the emergency room. BMC Infect Dis 2014; 14: 623. http://dx.doi:10.1186/s12879-014-

0623-z.

4.   Wilder-Smith A, Tissera H, Ooi EE, Coloma J, Scott TW, Gubler DJ. Preventing dengue

epidemics during COVID-19 pandemic. Am J Trop Med Hyg 2020; 103: 570-571.

http://dx.doi: 10.4269/ajtmh.20-0480.

5.   Gérardin P, Guernier V, Perrau J, Fianu A, Le Roux K, Grivard P, et al. Estimating

Chikungunya prevalence in La Réunion island outbreak by serosurveys: two methods for

two critical times of the epidemic BMC Infect Dis 2008; 8: 99. http://dx.doi:10.1186/1471-

2334-8-99.

6.   Vincent M, Larrieu S, Vilain P, Etienne A, Solet JL, François C, et al. From the threat to

the large outbreak: dengue on Reunion island. Euro Surveill 2019; 24: 1900346.

http://dx.doi: 10.2807/1560-7917.ES.2019.24.47.1900346.

7.   Wilkinson DA, Lebarbenchon C, Atyame C, Hafsia S, Jaffar-Bandjee MC, Menudier-Yemandja L, et

al. Genomic insights into early SARS-CoV-2 strains isolated in Reunion Island. MedRxiv 2021 Jan

6. https://doi.org/10.1101/2021.01.21.21249623.

8.   Wynants L, Van Calster B, Collins GS, Riley RD, Heinze G, Schuit E, et al. Prediction

models for diagnosis and prognosis of covid-19: systematic review and critical appraisal. BMJ

2020;369:m1328. https://dx.doi.org/10.1136/bmj.m1328.

9.   Joubert A, Andry F, Bertolotti A, Accot F, Koumar Y, Legrand F, et al. Distinguishing non

severe cases of dengue from COVID-19 in the context of co-epidemics: a cohort study in

a SARS-CoV-2 testing center on Reunion island. PLoS Negl Trop Dis 2021; 15:

e0008879. https://dx.doi/10.1371/journal.pntd.8879.

10. Leening MJG, Steyerberg EW, Van Calster B, D'Agostino RB, Pencina MJ. Net reclassification

improvement and integrated discrimination improvement require calibrated models: relevance

from a marker and a model perspective. Stat Med 2014; 33: 3415-8. https://dx.doi/10.

1002/sim.6133.

11. Marty FM, Chen K, Verrill KA. How to obtain a nasopharyngeal swab specimen. New Engl J Med

2020; 382; e76. https://dx.doi/10.1056/NEJMvcm2010260.

12. Fagerland MW, Hosmer DW. A generalized Hosmer-Lemeshow goodness-of-fit test for

multinomial logistic regression models. Stata Journal 2012; 12: 447-53.

https://dx.doi/10.1177/1536867X1201200307.

13. Verbackel JY, Steyerberg EW, Uno H, De Cock B, Wynants L, Collins GS, et al. ROC curves for

clinical prediction models part 1. ROC plots showed no added value to the AUC when evaluating

the performance of clinical prediction models. J Clin Epidemiol 2020; 126: 207-15.

https://dx.doi/10.1016/j.clinepi.2020.01.028.

14. Van Calster B, Wynants L, Collins GS, Verbackel JY, Steyerberg EW. ROC curves for clinical

prediction models part 3. The ROC plot: a picture that needs a 1000 words. J Clin Epidemiol

2020; 126: 220-3. https://dx.doi/10.1016/j.clinepi.2020.05.037.

15. Van Calster B, Nieboer D, Vergouwe Y, De Cock B, Pencina MJ, Steyerberg EW. A calibration

hierarchy for risk models was defined: from utopia to empirical data. Stat Med 2016; 74: 167-76.

https://dx.doi/10.1016/j.jclinepi.2015.12.005.

16. Lemeshow S, Hosmer DW. A review of goodness of fit statistics for use in the development of

logistic regression models. Am J Epidemiol 1982; 115: 92–8.

https://dx.doi/10.1093/oxfordjournals.aje.a113284.

17. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP; STROBE Initiative.

The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE)

statement: guidelines for reporting observational studies. PLoS Med 2007; 4: e296.

https://dx.doi/10.1371/journal.pmed.0040296.

18. Collins GS, Reitsma JB, Altman DG, Moons KG. Transparent reporting of a multivariable

prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD Statement. BMC

Med 2015; 13: 1. https://dx.doi/10.1186/s12916-014-0241-z.

19. Leteurtre S, Martinot A, Duhamel A, Proulx F, Grandbastien B, Cotting J, et al. Validation of the

paediatric logistic organ dysfunction (PELOD) score: prospective, observational, multicentre

study. Lancet 2003; 362: 192-7. https://dx.doi/10.1016/S0140-6736(03)13908-6.

20. Nowak MD, Sordillo EM, Gitman MR, Paniz-Mondolfi AE. Coinfection in SARS-CoV-2 infected

patients: Where are influenza virus and rhinovirus/enterovirus? J Med Virol 2020; 92: 1699-

1700. https://dx.doi/10.1002/jmv.25953. Epub 2020 Jul 17.

21. Jin-Jung Y, Campèse C, Lévy-Bruhl D, Savitch Y; Santé Publique France. Grippe: bilan de la saison

2019-2020. Chêne G ed: 2020 Oct 13; 10: 1-10. https://www.santepubliquefrance.fr/maladies-

et-traumatismes/maladies-et-infections-respiratoires/grippe/documents/bulletin-

national/bulletin-epidemiologique-grippe.-bilan-de-la-surveillance-saison-2019-2020.

22. Lokida D, Lukman N, Salim G, Butar-butar DP, Kosasih H, Wulan WN, et al. Diagnosis of COVID-19

in a dengue-endemic area. Am J Trop Med Hyg. 2020; 10: 1220-2. https://dx.doi/

10.4269/ajtmh.20-0676.

23. Vanroye F, Van den Bossche D, Brosius I, Tack B, Van Esbroek M, Jacobs J. COVID-19 antibody

detecting rapid diagnostic tests show high cross-reactivity when challenged with pre-pandemic

malaria, schistosomiasis and dengue samples. Diagnostics (Basel) 2021; 11: 1163. https://dx.doi/

10.3390/diagnostics11071163.

24. Khandker SS, Nik Hashim NHH, Deris ZZ, Shueb RH, Islam MA. Diagnostic accuracy of rapid

antigen test kits for detecting SARS-CoV-2: a systematic review and meta-analysis of 17,171

suspected COVID-19 patients. J Clin Med 2021; 10: 3493. https://dx.doi/10.3390/jcm10163493.

25. Van Calster B, Steyerberg EW, Harrell FH. Risk prediction for individuals. JAMA 2015; 314: 1875.

https://dx.doi/10.1001/jama.2015.12215.

26. Van Calster B, Vergouwe Y, Looman CWN, Van Belle V, Timmerman D, Steyerberg EW. Assessing

the discriminative ability of risk models for more than two outcome categories. Eur J Epidemiol

2012; 27: 761–70. https://dx.doi/10.1007/s10654-012-9733-3.

27. Van Hoorde K, Vergouwe Y, Timmerman D, Van Huffel S, Steyerberg EW, Van Calster B.

Assessing calibration of multinomial risk prediction models. Stat Med 2014; 33: 2585-96.

https://dx.doi/10.1002/sim.6114.

28. Usman MS, Siddiqi TJ, Khan MS, Patel UK, Shahid I, Ahmed J, et al. Is there a smoker's paradox in

COVID-19?   BMJ   Evid   Based   Med.   2020   Aug   11:bmjebm-2020-111492.

https://dx.doi/10.1136/bmjebm-2020-111492. Online ahead of print.

29. Chu DK, Akl EA, Duda S, Solo K, Yaacoub S, Schünemann HJ, COVID-19 Systematic Urgent Review

Group Effort (SURGE) Study Authors. Physical distancing, face masks, and eye protection to

prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and

meta-analysis. Lancet 2020; 395: 1973-87. https://dx.doi/0.1016/S0140-6736(20)31142-9. Epub

2020 Jun 1.

30. Buitrago-Garcia D, Egli-Gany D, Counotte MJ, Hossmann S, Imeri H, Ipekci AM et al. Occurrence and

transmission potential of asymptomatic and presymptomatic SARSCoV-2 infections: A living

systematic   review   and   meta-analysis.   PLoS   Med.   2020;   17:   e1003346.   https://dx.doi/

10.1371/journal.pmed.1003346. eCollection 2020 Sep.

31. Premaratna R, Pathmeswaran A, Amarasekara NDDM, Motha MBC, Perera KVHKK, de Silva HJ. A

clinical guide for early detection of dengue fever and timing of investigations to detect patients

likely to develop complications. Trans R Soc Trop Med Hyg 2009;103: 127-31. https://dx.doi/10.

1016/j.trstmh.2008.07.024.

32. Riddell A, Babiker ZO. Imported dengue fever in East London: a 6-year retrospective

observational study. J Travel Med 2017; 24: 1-6. https://dx.doi/10.1093/jtm/tax015.

33.   El-Anwar MW, Eesa M, Mansour W, Zake LG, Hendawy E. Analysis of Ear, Nose and Throat

595   Manifestations in COVID-19 Patients. Int Arch Otorhinolaryngol. 2021; 25: e343-e348.

596   https://dx.doi/10.1055/s-0041-1730456.

597   34.   Gu W, Deng X, Reyes K, Hsu E, Wang C, Sotomayor-Gonzalez A, et al. Associations of early

598   COVID-19 cases in San Francisco with domestic and international travel. Clin Infect Dis 2020; 71:

599   2976-80. https://dx.doi/10.1093/cid/ciaa599.

600   35.   Krol P, Coolen-Allou N, Teysseyre L, Traversier N, Beasley F, Nativel M, et al. Differential

601   diagnoses of severe COVID-19 in tropical areas: the experience of Reunion Island. Trop Med Int

602   Health 2021; 26: 444-52. https://dx.doi/10.1111/tmi.13542.

603   36.   Nicolete VC, Rodrigues PT, Johansen IC, Corder RM, Tonini J, Cardoso MA et al. Interacting

604   epidemics in Amazonian Brazil: prior dengue infection associated with increased COVID-19 risk

605   in   a   population-based   cohort   study.   Clin   Infect   Dis   2021;   ciab410.

606   https://dx.doi/10.1093/cid/ciab410. Online ahead of print.

607   37.   Simons D, Shahab L, Brown J, Perski O. The association of smoking status with SARS-CoV-2

608   infection, hospitalization and mortality from COVID-19: a living rapid evidence review with

609   Bayesian analyses (version 7). Addiction 2021; 116: 1319-68. https://dx.doi/10.1111/add.15276.

610   Epub 2020 Nov 17.

611   38.   Romero-Gameros CA, Colin-Martínez T, Waizel-Haiat S, Vargas-Ortega G, Ferat-Osorio E,

612   Guerrero-Paz JA, et al. Diagnostic accuracy of symptoms as a diagnostic tool for SARS-CoV 2

613   infection: a cross-sectional study in a cohort of 2,173 patients. BMC Infect Dis. 2021; 21: 255.

614   https://dx.doi/10.1186/s12879-021-05930-1.

615   39.   Rosso F, Parra-Lara LG, Agudelo-Rojas OL, Martinez-Ruiz DM. Differentiating dengue from

616   COVID-19: comparison of cases in Colombia. Am J Trop Med Hyg 2021; tpmd200912.

617   https://dx.doi/10.4269/ajtmh.20-0912. Online ahead of print.

40. Ruiy W, Hsu SY, Tsai HL, CT Chen. COVID-19 mimicking dengue fever with the initial

manifestation of retro-orbital pain – a rare case. J Formos Med Assoc 2020; 119: 1715-16.

https://dx.doi/10.1016/j.jfma.2020.05.039. Epub 2020 Jun 4.

41. Guzman MG, Gubler DJ, Izquierdo A, Martinez E, Haldstead SB. Dengue infection. Nat Rev Dis

Primers 2016; 2: 16055. https://dx.doi/10.1038/nrdp.2016.55.

42. Challen R, Brooks-Pollock E, Read JM, Dyson L, Tsaneva-Atanasova K, Danon L. Risk of mortality

in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort study. BMJ

2021; 372: n579. https://dx.doi/10.1136/bmj.n579.

43. Faria NR, Mellan TA, Whittaker C, Claro IM, Candido DdS, Mishra S, et al. Genomics and

epidemiology of the P1.SARS-CoV-2 lineage in Manaus, Brazil. Science 2021; 372(6544): 815-21.

https://dx.doi/10.1126/science.abh.2644. Epub 2021 Apr 14.

44. Puech B, Legrand A, Simon O, Combe C, Jaffar-Bandjee MC, Caron M, et al. Prognosis of

critically-ill patients with acute respiratory failure due to SARS-CoV-2 (501Y.V2) variant: a

multicenter retrospective matched cohort study. Research Square 2021. https://dx.doi/

10.21203/rs.3.rs-80608v2.

45. Ong SWX, Chiew CJ, Ang LW, Mak TM, Cui L, Toh MPHS, et al. Clinical and virological features of

SARS-CoV-2 variants of concern: a retrospective cohort study comparing B.1.1.7 (Alpha), B.1.315

(Beta), and B.1.617.2 (Delta). Clin Infect Dis 2021; ciab721. https://dx.doi/

10.1093/cid/ciab721. Online ahead of print.

Table 1. Final best fit multinomial logistic regression model distinguishing the independent predictors of COVID-19 and dengue from those of other febrile illnesses among 969 participants who consulted at a COVID-19 screening center in Saint Pierre (Reunion Island) during the COVID-19 dengue co-epidemics from 23 March to 10 May 2020

Outcomes (versus other febrile illnesses as controls*) Predictors	COVID-19 (N = 73)					Dengue (N = 60)				
	n	CIR, (%)	aOR	95% CI	Points	n	CIR, (%)	aOR	95% CI	Points
Contact with a COVID-19 positive case	40	15.38	**4.26**	**2.33 to 7.78**	+ 3	6	2.31	0.71	0.26 to 1.87	0
Return from travel abroad < 15 days	38	16.03	**3.53**	**2.05 to 6.05**	+ 3	6	2.53	0.41	0.15 to 1.05	- 1
Previous individual episode of dengue	4	9.06	2.16	0.56 to 8.29	+ 1	9	20.45	**4.50**	**1.68 to 12.00**	+ 3
Active smoker †	4	2.53	**0.25**	**0.09 to 0.67**	- 3	12	7.59	1.38	0.65 to 2.91	0
Cough	32	6.82	0.95	0.53 to 1.68	0	17	3.62	**0.36**	**0.18 to 0.70**	- 2
Body ache ‡	29	7.09	1.26	0.70 to 2.24	0	52	12.71	**6.35**	**2.56 to 15.71**	+ 5
Anosmia	26	27.96	**7.64**	**4.13 to 14.12**	+ 7	3	3.23	0.47	0.11 to 2.01	- 1
Headache	28	5.70	0.92	0.54 to 1.55	0	55	11.20	**5.51**	**1.85 to 16.41**	+ 5
Retro-orbital pain	1	2.27	0.53	0.06 to 4.53	- 1	17	38.64	**4.42**	**2.03 to 9.59**	+ 5
Upper respiratory tract infection symptoms #	28	5.63	0.53	**0.31 to 0.90**	- 1	20	4.02	**0.51**	**0.26 to 0.98**	- 1
Presentation > 3 days after symptom onset	53	9.55	1.71	0.94 to 3.10	+ 1	24	4.32	0.75	0.39 to 1.42	0

Multinomial logistic regression model with other non COVID-19 non dengue febrile illnesses*, taken as controls. Data are numbers, cumulative incidence rates (CIR) expressed as percentages, adjusted odd ratios (aOR), 95% confidence intervals (95% CI). † Current smoker, as compared to never smoker and past smoker; ‡ muscle pain or backache with tightness and/or stiffness; # sore throat, runny nose, nasal congestion, or sneezing. 44 Participants with missing data excluded from the model (1013-969) of whom 42 had missing information on the delay of presentation, 1 on the return from travel abroad, 1 on a previous episode of dengue. The indicators of performance of the model are as follows: Bayesian information criterion -5709, Goodness of fit chi-2 test's probability 0.31, areas under the receiver operating characteristic curves 0.80 (95%CI 0.74-0.86) and 0.89 (95%CI 0.84-0.92), respectively. For COVID-19 prediction, the estimated probability of being infected is $\text{Prob}_{(Y=1/x)} = 1/(1 + \exp^{-(-3.82 + \sum_i \beta_i \times X_j)})$ and the beta coefficients of the model are as follows: $\sum \beta_i \times X_j = 1.45 X_1 + 1.26 X_2 + 0.77 X_3 - 1.37 X_4 - 0.05 X_5 + 0.23 X_6 + 2.03 X_7 - 0.08 X_8 - 0.63 X_9 - 0.64 X_{10} + 0.54 X_{11}$ and intercept coefficient is - 3.82. For dengue prediction, the estimated probability of being infected is $\text{Prob}_{(Y=1/x)} = 1/(1 + \exp^{-(-4.40 + \sum_i \beta_i \times X_j)})$ and the beta coefficients of the model are as follows: $\sum \beta_i \times X_j = - 0.35 X_1 - 0.90 X_2 + 1.50 X_3 + 0.32 X_4 - 1.02 X_5 + 1.85 X_6 - 0.75 X_7 + 1.71 X_8 + 1.49 X_9 - 0.66 X_{10} - 0.29 X_{11}$ and intercept coefficient is - 4.40.

Figures

Figure 1. Study population for differentiating dengue and COVID-19 from other febrile illnesses in co-

epidemics

Figure 2. Discriminative ability of the final model and of COVIDENGUE scores for COVID-19 and dengue at Saint-Pierre, Reunion Island from 23 March to 10 May 2020

Notes: Areas under receiver operating characteristic (AUC) curves are given for the best fit compromise final models (reference models) and the COVIDENGUE scores before validation by bootstrapping. The better the model or the score discriminates, the more the ROC curve approaches the upper left corner of the plot. A model with no discriminative ability has a true ROC curve that lies on the diagonal line.

Figure 3. Diagnostic performances of the COVIDENGUE scores